Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in chronic pulmonary sarcoidosis
NL-OMON46232Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in pulmonary sarcoidosis, sarcoidosis, sponsored by Novartis. Started Dec 2016; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
pulmonary sarcoidosissarcoidosis
Beyond the preview
Go deeper on NL-OMON46232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46232.